Treatment of Moderate or Severe HHT-Related Gastrointestinal Bleeding
When gastrointestinal bleeding in hereditary hemorrhagic telangiectasia reaches a burden requiring intravenous iron replacement or red cell transfusion, the clinical picture demands a structured, protocol-driven approach. This page outlines the defined patient population and gives a partial overview of the recommended management.
Clinical scenario
Moderate HHT-related GI bleeding describes a patient who meets haemoglobin goals with intravenous iron treatment.
Severe HHT-related GI bleeding describes a patient who does not meet haemoglobin goals despite adequate iron replacement, or who requires blood transfusions.
Both groups share a key threshold: dependence on parenteral iron or transfusion support to sustain haemoglobin targets.
Approach — partial overview
The protocol includes a procedural haemostatic option — Argon Plasma Coagulation directed at acutely bleeding gastrointestinal vascular lesions — reserved for specific, narrowly defined circumstances. The complete decision algorithm, full scope of recommended interventions, and applicable thresholds are available in the structured protocol.
References
DOI: 10.1182/blood.2020008739
- Moderate HHT-related GI bleeding: patient who meets their hemoglobin goals* with IV iron treatment.
- Severe HHT-related GI bleeding: patient who does not meet their hemoglobin goals* despite adequate iron replacement or requires blood transfusions.
- Procedural hemostatic treatments, including Argon Plasma Coagulation, are recommended only to treat an emergent, brisk bleed or acutely bleeding GI vascular lesions visualized at the time of diagnostic endoscopy, because there are insufficient data to support their systematic and repeated use to minimize the telangiectasia burden.
View source ↗